
Image credit: Impulse Dynamics Note: The OPTIMIZER Integra CCM-D System is an investigational device. It is not available for sale in the United States.
Yesterday, Dr. Niraj Varma, on behalf of the INTEGRA-D investigators, presented data for the efficacy phase of the clinical trial of the combined Cardiac Contractility Modulation/Defibrillator System (OPTIMIZER Integra CCM-D). The results were presented at a late-breaking clinical trial session at the 2025 Heart Rhythm conference in San Diego, CA.
This is a very important step for Impulse Dynamics – the company for which I serve as CTO and Executive VP – towards bringing to market a single device which combines our proprietary CCM therapy for the treatment of HF symptoms with implantable cardioverter defibrillator (ICD) therapy.
In the trial, the OPTIMIZER Integra CCM-D device successfully converted 100% of ventricular fibrillation (VF) induced in 100 consecutive patients, meeting the primary efficacy endpoint. The Company’s press release is available here.
Note: The OPTIMIZER Integra CCM-D System is an investigational device. It is not available for sale in the United States.